Therefore, pyrotinib is currently being evaluated in a phase 3 PYRAMID-1 study, which compares it with docetaxel in patients with advanced HER2 MUT (Ex20) NSCLC after platinum-based chemotherapy (NCT04447118). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.